Novartis' drug Gilenya fails to help in primary-progressive MS; AbbVie donates children's HIV meds to patient pool;

@FiercePharma: Zoetis R&D chief Catherine Knupp on the fight to stay atop animal health. FierceAnimalHealth article | Follow @FiercePharma

@CarlyHFierce: UPDATED with a statement from $NVS - Novartis flu vaccine under the lens as Italy probes 13 deaths. Article | Follow @CarlyHFierce

> Novartis ($NVS) reports that Gilenya failed to outperform a placebo in patients with primary-progressive multiple sclerosis. Story

> GlaxoSmithKline ($GSK) fired an executive who complained about discrimination in the company's  South African unit when he failed to appear for a performance plan. Story

> Gilead Sciences ($GILD) has given generics maker Mylan nonexclusive rights to manufacture in 112 countries cheaper versions of an investigational HIV med, assuming it is approved. Story

> AbbVie ($ABBV) has agreed to donate to the non-profit Medicines Patent Pool (MPP), two HIV meds approved for children. Story

> Pfizer ($PFE) has completed its $635 million buyout of the marketed vaccines portfolio of Baxter International ($BAX). Release

> The European Commission has approved Boehringher Ingelheim's Vargatef (nintedanib) in combination with docetaxal for use in adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) after first-line chemotherapy. Story

Medical Device News

@FierceMedDev: ICYMI: U.K. and Wellcome Trust back trial of new, 15-minute Ebola test in West Africa. FierceDiagnostics article | Follow @FierceMedDev

@EmilyWFierce: Merck KGaA will hold onto its consumer health biz--for now. FiercePharma story | Follow @EmilyWFierce

> Harvard researchers using 3-D printing to create customized airway stents. Report

> Philips to focus on informatics as part of HealthTech restructure. Story

> Study shows artificial pancreas improves treatment for Type 1 diabetes. Article

Biotech News

@FierceBiotech: After numerous setbacks, $LLY mounts another pivotal assault on Alzheimer's. More | Follow @FierceBiotech

@JohnCFierce: Takeda gets a BTD designation on ixazomib (MLN9708), for the treatment of relapsed or refractory systemic light-chain (AL) amyloidosis. | Follow @JohnCFierce

@DamianFierce: In which hackers trick bankers into tipping them off to biopharma buyouts. Story | Follow @DamianFierce

> Fresh from a $3.85B deal, biotech CEO sets sights on the next big thing. Story

> Top research institutions hand hot gene-editing tech--with a catch--to Editas. More

> Buzz: Deep job cuts looming at GlaxoSmithKline's U.S. ops in RTP, Philly. Article

> As PDUFA looms Sanofi punts a $35M partnership. Item

CRO News

> Almac partners up to keep patients--and data--safe in trial emergencies. More

> WuXi pairs up with deCODE spinout to further its genomics expansion. News

> GVK gets its drug repurposing tech into Japan with new partnership. Story

> Quintiles pools postmarketing services into a single offering. Item

> Accovion reaches into France amid expansion kick. Article

Biotech IT News

> U.K. heavyweights commit $16M to Oxford Uni genome data analysis spinout. Report

> Texas' $3B cancer agency makes computational biology a priority. News

> Nvidia backs projects to tap GPUs for cancer research. Story

> Humana agrees to contribute information to PearlDiver's database. Article

> Monocl Software bags grant for KOL assessment platform. More

Animal Health News

> Bayer launches smartphone app to help farmers monitor dairy herd health. Story

> Natura Pet issues 8-state voluntary recall of cat food; Canada included. More

> IDEXX aids in discovery of new biomarker to spot early kidney disease in cats. Item

> Dutch set safety corridor as a bird flu hits a fourth poultry farm. News

> Nova Scotia establishes program to support beef industry and safety standards. Article

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.